The bioluminescent calcium indicator aequorin was chemically loaded into isolated strips of ferret portal vein and ferret aorta. Aequorin light emission (a function of [Ca2+]i) was recorded simultaneously with tension. Assuming an [Mg2+]i of 0.5 mM, [Ca2+]i was 1.8 X 10(-7) M in the unstimulated portal vein at 22 degrees C where there was negligible resting tone. In contrast, in the unstimulated aorta at 22 degrees C where there was significant basal tone, the [Ca2+]i was 2.7 X 10(-7) M. In both portal vein and aorta, potassium depolarization caused a monophasic rise in intracellular Ca2+ in parallel with the rise in tension, whereas phenylephrine caused an initial spike of light during the period of the force development which then fell to a much lower plateau level during the period of force maintenance. Calcium-force curves were generated by plotting calibrated aequorin light against force while intracellular [Ca2+] was made to change either by increasing degrees of potassium depolarization or decreasing extracellular [Ca2+]. The steady-state calcium-force curve in the presence of phenylephrine was shifted to the left of the curve in the presence of potassium depolarization in both the portal vein and aorta. In the aorta there was a counter-clockwise hysteresis in the calcium-force relationship. In contrast, in the portal vein there was no demonstrable hysteresis, indicating that the apparent change in calcium sensitivity of the contractile apparatus in the presence of phenylephrine must be caused by a second messenger other than calcium.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1192648PMC
http://dx.doi.org/10.1113/jphysiol.1985.sp015900DOI Listing

Publication Analysis

Top Keywords

portal vein
20
potassium depolarization
12
aequorin light
8
[ca2+]i 10-7
8
vein aorta
8
phenylephrine caused
8
period force
8
curve presence
8
presence phenylephrine
8
portal
5

Similar Publications

Purpose: We present the case of a rare extrahepatic portocaval shunt that resulted in communication of the portal vein and the inferior vena cava (IVC) at the level between two right renal veins that was incidentally diagnosed with contrast-enhanced computed tomography (CECT) in an asymptomatic patient.

Methods: A woman in her sixties with abdominal pain and diarrhea of unclear origin underwent exploratory abdominal CECT.

Results: The CECT incidentally revealed an extrahepatic portocaval shunt, whereby a vessel arising from the portal vein superior to the confluence of the superior mesenteric and splenic veins drained into the posterior aspect of the IVC between two right renal veins.

View Article and Find Full Text PDF

Background: Pancreatic cancer involving the pancreas neck and body often invades the retroperitoneal vessels, making its radical resection challenging. Multimodal treatment strategies, including neoadjuvant therapy, surgery, and postoperative adjuvant therapy, are contributing to a paradigm shift in the treatment of pancreatic cancer. This strategy is also promising in the treatment of pancreatic neck-body cancer.

View Article and Find Full Text PDF

Background: Cirrhotic patients with super-giant hepatocellular carcinoma (HCC) and portal vein invasion generally have a poor prognosis. This paper presents a patient with super-giant HCC and portal vein invasion, who underwent hepatectomy followed by a combination of sorafenib and camrelizumab, resulting in complete remission (CR) for 5 years.

Case Summary: A 40-year-old male with compensated hepatitis B-related cirrhosis was diagnosed with HCC, Barcelona Clinic Liver Cancer stage C.

View Article and Find Full Text PDF

Portal vein thrombosis (PVT) typically arises in patients with underlying cirrhosis, hepatobiliary malignancies, abdominal inflammatory conditions, or hematologic disorders. However, in non-cirrhotic individuals, PVT is less common and may initially present with minimal symptoms, escalating significantly if it extends to the mesenteric veins. Here, we present the case of a 37-year-old male with combined portal and mesenteric venous thrombosis, manifesting as acute intestinal obstruction.

View Article and Find Full Text PDF

Background And Aims: Real-world data on the variceal bleeding (VB) risk in patients receiving atezolizumab-bevacizumab (Atezo-Bev) treatment remain limited. This study aimed to assess the risk of VB and identify risk factors in patients with advanced hepatocellular carcinoma (HCC) receiving Atezo-Bev treatment.

Methods: This retrospective study included 640 patients with HCC who underwent endoscopy before Atezo-Bev treatment at two hospitals in Korea.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!